Skip to main content
SpringerLink
Log in

Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

We investigated the influence of various clinical prognostic factors in patients with glioblastoma multiforme (GBM) treated with a combined modality approach. A total of 175 patients with GBM was treated in four consecutive prospective phase II studies using surgery, hyperfractionted or accelerated hyperfractionated radiotherapy (RT) and either adjuvant or concurrent or pre-irradiation chemotherapy (CHT) between Janaury 1988 and December 1993. The median survival time for all 175 patients was 14 months and 1–3-year survival (OS) rates were 57%, 34% and 24%, respectively. The median time to tumour progression was 12 months, and 1–3-year progression-free survival (PFS) rates were 43%, 11% and 7%, respectively. Survival analysis showed that of all investigated prognostic factors, only gender did not influence survival. Patients ≤55 years did better than those >55 years; patients with KPS 80–100 did better than those with KPS 50–70; patients with frontal tumours did better than those with tumours in other locations; patients with tumours up to 4 cm did better than those with larger tumours, as did patients with either subtotal or gross total tumour resection when compared to those undergoing biopsy only. Multivariate analysis showed that gender and tumour location did not independently influence survival. When PFS was used as the endpoint, only gender did not influence PFS, as confirmed by multivariate analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

Similar content being viewed by others

References

  1. Deutch M, Green SB, Strike TA, et al (1989) Results of randomized trial comparing BCNU plus radiotherapy, streptozocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidasole plus radiotherapy in the post-operative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16:1389–1396

    PubMed  Google Scholar 

  2. Kristiansen K, Hagen S, Kollevold T, et al (1981) Combined modality therapy of operated astrocytomas Grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study group. Cancer 47:649–652

    PubMed  Google Scholar 

  3. Nelson DF, Diener-West M, Weinstein AS, et al (1986) A randomized comparison of misonidasole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 12:1793–1800

    PubMed  Google Scholar 

  4. Salazar OM, Rubin P, Feldstein ML, Pizzutiello R (1979) High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 5:1733–1740

    CAS  PubMed  Google Scholar 

  5. Kolker JD, Halpern HJ, Krishnasamy S, et al (1990) "Instant-mix" whole brain photon with neutron boost radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 19:409–414

    PubMed  Google Scholar 

  6. Jeremic B, Jovanovic D, Djuric L, Jevremovic S, Mijatovic L (1992) Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine and vincristine (mPCV) over chemotherapy with VM-26 and CCNU. J Chemother 4:123–126

    PubMed  Google Scholar 

  7. Levin VA, Silver P, Hannigan J, et al (1980) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic astrocytoma: NCOG 6G91 final report. Int J Radiat Oncol Biol Phys 18:321–324

    Google Scholar 

  8. Jeremic B, Grujicic D, Antunovic V, Djuric Lj, Stojanovic M, Shibamoto Y (1994) Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study. Int J Radiat Oncol Biol Phys 30:1179–1185

    PubMed  Google Scholar 

  9. Jeremic B, Grujicic D, Antunovic V, Djuric Lj, Shibamoto Y (1995) Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. Am J Clin Oncol (CCT) 18:449–453

    Google Scholar 

  10. Nelson DF, Curran WJ Jr, Scott CB, et al (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma: possible advantage observed at 72.0 Gy in 1.2 Gy b.i.d. fractions: report of the Radiation Therapy Oncology Group protocol 8302. Int J Radiat Oncol Biol Phys 25:193–207

    PubMed  Google Scholar 

  11. Sneed PK, Gutin PH, Larson DA, et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719–727

    PubMed  Google Scholar 

  12. Mehta MP, Masciopinto J, Rozental J, et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541–549

    PubMed  Google Scholar 

  13. Shrieve DC, Alexander E 3rd, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS (1994) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90:72–77

    Google Scholar 

  14. Regine WF, Patchell RA, Strottmann JM, Meigooni A, Sanders M, Young AB (2000) Preliminary report of a phase I study of combined fractionated stereotactic radiosurgery and conventional external beam radiation therapy for unfavourable gliomas. Int J Radiat Oncol Biol Phys 48:421–426

    Article  PubMed  Google Scholar 

  15. Cardinale RM, Schmidt-Ullrich RK, Benedict SH, Zwicker RD, Han DC, Broaddus WC (1998) Accelerated radiotherapy regimens for malignant gliomas using stereotactic concomitant boosts for dose escalation. Radiat Oncol Investigat:175–181

    Article  Google Scholar 

  16. Shiu A, Kooy H, Ewton J (1997) Comparison of miniature multileaf collimation (MMLC) with circular collimation for stereotactic treatment. Int J Radiat Oncol Biol Phys 37:679–688

    Article  PubMed  Google Scholar 

  17. Khoo VS, Oldham M, Adams EJ, Bedford JL, Webb S, Brada M (1999) Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys 45:415–425

    Article  PubMed  Google Scholar 

  18. Woo SY, Granbt III WH, Belleza D (1996) A comparison of intensity modulated conformal therapy with aconventional external beam stereotactic radiosurgery system for the treatment of single and multiple intracranial lesions. Int J Radiat Oncol Biol Phys 35:593–597

    PubMed  Google Scholar 

  19. Pirzkall A, McKnight TR, Graves EE et al (2001) MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 50:915–928

    Article  PubMed  Google Scholar 

  20. Biersack HJ, Coenen HH, Stocklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann (1989) Imaging of brain tumors with L-3-(123I)iodo-alpha-methyl-L-tirosine. J Nucl Med 30:110–112

    Google Scholar 

  21. Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner D, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M (1997) Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 38:802–808

    CAS  PubMed  Google Scholar 

  22. Gross MW, Weber W, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M (1998) The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatmnt planning of malignant gliomas. Int J Radiat Oncol Biol Phys 41:989–995

    Article  PubMed  Google Scholar 

  23. Grosu A-L, Weber W, Feldmann HJ, Wuttke B, Bartenstein P, Gross MW, Lumenta C, Schwaiger M, Molls M (2000) First experience with I-123-alpha-methyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 47:517–526

    Article  CAS  PubMed  Google Scholar 

  24. Grosu A-L, Feldmann HJ, Dick S, Dzewas B, Nieder C, Gumprecht H, Frank A, Schwaiger M, Molls M, Weber WA (2002) Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 54:842–854

    Google Scholar 

  25. Glatstein E, Makuch RW (1984) Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol 2:488–497

    CAS  PubMed  Google Scholar 

  26. Simon R (1984) Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 68:185–192

    CAS  PubMed  Google Scholar 

  27. Curran WJ Jr, Scott CB, Horton J, et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710

    PubMed  Google Scholar 

  28. Jeremic B, Shibamoto Y, Grujicic D, et al (1999) Preirradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas. A phase II study. Radiother Oncol 51:27–33

    Article  PubMed  Google Scholar 

  29. Jeremic B, Shibamoto Y, Grujicic D, et al (2001) Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neuro-Oncol 51:133–141

    Google Scholar 

  30. Hulshof MCCM, Schimmel EC, Bosch AD, Gonzalez DG (2000) Hypofractionation in glioblastoma multiforme. Radiother Oncol 54:143–148

    Article  PubMed  Google Scholar 

  31. Simpson JR, Horton J, Scott C, et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239–244

    PubMed  Google Scholar 

  32. Kreth FW, Warnke PC, Scheremet R, Ostertag CB (1993) Surgical resection and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 78:762–766

    CAS  PubMed  Google Scholar 

  33. Kreth FW, Berlis A, Spiropoulou V, et al (1999) The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 86:2117–2123

    Article  PubMed  Google Scholar 

  34. Lacroix M, Abi-Said D, Fourney DR, et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme. J Neurosurg 95:190–198

    Article  CAS  Google Scholar 

  35. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T (2001) Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 52:161–171

    Article  PubMed  Google Scholar 

  36. Gamburg ES, Regine WF, Patchell RA, Strotmann JM, Mohiuddin M, Young AB (2000) The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 48:1359–1362

    Article  PubMed  Google Scholar 

  37. Jeremic B, Grujicic D, Antunovic V, Stojanovic M, Shibamoto Y (1994) Influence of the extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol 21:177–185

    PubMed  Google Scholar 

  38. Jelsma R, Bucy PC (1967) The treatment of glioblastoma multiforme of the brain. J Neurosurg 27:388–400

    PubMed  Google Scholar 

  39. Jelsma R, Bucy PC (1969) Glioblastoma multiforme. Its treatment and some factors effecting survival. Arch Neurol 20:161–171

    PubMed  Google Scholar 

  40. Kinsella TJ, Rowland CJ, Klecker R et al (1988) Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 6:876–879

    Google Scholar 

  41. Newall J, Ranshoff J, Kaplan B (1988) Glioblastoma in the older patient: how long a course of radiotherapy is necessary? J Neurooncol 6:325–327

    Google Scholar 

  42. Salcman M (1985) Resection and reoperation in neuro-oncology. Rationale and approach. Neurol Clin 3:831–842

    PubMed  Google Scholar 

  43. Salcman M (1987) Surgical decision-making for malignant brain tumors. Clin Neurosurg 35:285–313

    Google Scholar 

  44. Davis L, Martin J, Goldstein SL et al (1949) A study of 211 patients with verified glioblastoma multiforme. J Neurosurg 6:33–44

    Google Scholar 

  45. Andreou J, George AE, Wise A et al (1983) CT prognostic criteria of survival after malignant glioma surgery. AJNR 4:488–490

    CAS  Google Scholar 

  46. Hoshino T (1984) A commentary on the biology and growth kinetics of low-grade and high-grade gliomas. J Neurosurg 61:895–900

    CAS  PubMed  Google Scholar 

  47. Cushing H (1932) Intracranial tumors. Notes upon a series of 2,000 verified cases with surgical mortality percentages pertaining thereto. Thomas, Springfield

  48. Chang CH, Horton J, Schoenfeld D, et al (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52:997–1007

    CAS  PubMed  Google Scholar 

  49. Walker MD, Alexander E, Hunt WE, Mahaley MS, Ranshoff J, Gehan EA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333–343

    PubMed  Google Scholar 

  50. Quigley MR, Maroon JC (1991) The relationship between survival and the extent of resection in patients with supratentorial malignant gliomas. Neurosurgery 29:385–389

    CAS  PubMed  Google Scholar 

  51. Nazzaro JM, Neuwelt EA (1990) The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73:331–334

    PubMed  Google Scholar 

  52. Devaux BC, O'Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. J Neurosurg 78:767–775

    CAS  PubMed  Google Scholar 

  53. Kowalczuk A, Macdonald RL, Amidei C, et al (1997) Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:1028–1038

    CAS  PubMed  Google Scholar 

  54. Albert FK, Forsting M, Sartor K, Adams H-P, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45–61

    CAS  PubMed  Google Scholar 

  55. Coffey RJ, Lunsford LD, Taylor FH (1988) Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22:465–473

    PubMed  Google Scholar 

  56. Wood JR, Green SB, Shapiro WR (1988) The prognostic importance of tumor size in malignant gliomas: a computed tomography scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:338–343

    PubMed  Google Scholar 

  57. Hitchcock E, Sato F (1964) Treatment of malignant gliomata. J Neurosurg 21:497–505

    CAS  Google Scholar 

  58. Wurschmidt F, Buenemann H, Heilmann H-P (1995) Prognostic factors in high-grade malignant glioma. A multivariate analysis of 76 cases with postoperative radiotherapy. Strahlenther Onkol 171:315–321

    PubMed  Google Scholar 

  59. Hoshino T, Wilson CB, Rosenblum ML, et al (1975) Chemotherapeutic implications of growth and cell cycle time in glioblastomas. J Neurosurg 43:127–135

    PubMed  Google Scholar 

  60. Onoyama Y, Abe M, Yabumoto E, et al (1976) Radiation therapy in the treatment of glioblastoma. Am J Roentgenol 126:481–492

    PubMed  Google Scholar 

  61. Ramsay RG, Brand WN (1973) Radiotherapy of glioblastoma multiforme. J Neurosurg 39:197–202

    PubMed  Google Scholar 

  62. Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59:1617–1625

    CAS  PubMed  Google Scholar 

  63. Hoshino T, Prados M, Wilson CB, et al (1989) Prognostic significance of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71:335–341

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University Hospital, Kragujevac, Yugoslavia

    Branislav Jeremic, Biljana Milicic, Aleksandar Dagovic & Jasna Aleksandrovic

  2. Institute of Neurosurgery, University of Belgrade, Belgrade, Yugoslavia

    Danica Grujicic

  3. Department of Radiotherapy, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, 81675, Munich, Germany

    Branislav Jeremic

Authors
  1. Branislav Jeremic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Biljana Milicic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Danica Grujicic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aleksandar Dagovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jasna Aleksandrovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Branislav Jeremic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeremic, B., Milicic, B., Grujicic, D. et al. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129, 477–484 (2003). https://doi.org/10.1007/s00432-003-0471-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-003-0471-5

Keywords

Search

Navigation